Literature DB >> 6180054

Determination of human leukocyte populations involved in production of interferons alpha and gamma.

M Wiranowska-Stewart, W E Stewart.   

Abstract

Human mononuclear leukocyte populations separated into T-, B-, and monocyte-enriched fractions, were evaluated for their abilities to produce interferons when induced with either virus, double-stranded RNA or mitogens. The main producer of alpha-interferon was the B-cell enriched subpopulation, but these cells did not produce gamma-interferon. In contrast, the T-cell enriched population produced either alpha or gamma interferons, depending upon the type of inducer used. The monocyte-enriched population was also able to produce either alpha or gamma interferon. The presence of monocytes in T-cell enriched populations enhanced the levels of alpha interferon production, and removal of monocytes from T-cell enriched populations diminished levels of alpha interferon produced. Even though each of the mononuclear populations (B-, T-, and monocytes) were able to produce alpha-interferon in response to poly rI.polyrC, it was found, by using a single-cell production assay, that only about 0.1% of the total mononuclear population actually produced alpha-interferon when so induced. Similarly, using the single-cell production assay, it was demonstrated that gamma-interferon was produced by only a small proportion of induced T-cells (possibly on T-cell subpopulation), as only about 1 T-cell per 1,000 responded to PHA by production of gamma-interferon.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6180054     DOI: 10.1089/jir.1981.1.233

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  14 in total

Review 1.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

3.  Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity.

Authors:  R Cauda; S K Tyring; C E Grossi; A B Tilden; K D Hatch; W M Sams; S Baron; R J Whitley
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

4.  Effects of pure interferons on Epstein-Barr virus infection in vitro.

Authors:  J P Andersson; U G Andersson; I T Ernberg; S F Britton; M DeLey
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

5.  Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production.

Authors:  V Chopra; S K Tyring; L Johnson; J D Fine
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

6.  Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune encephalomyelitis.

Authors:  G Stoll; S Müller; B Schmidt; P van der Meide; S Jung; K V Toyka; H P Hartung
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

7.  I-E/I-C region-associated induction of murine gamma interferon by a haplotype-restricted polyclonal T-cell mitogen derived from Mycoplasma arthritidis.

Authors:  B C Cole; R N Thorpe
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

8.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.

Authors:  B W Robinson; T L McLemore; R G Crystal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Induction of gamma-interferon activity by elevated temperatures in human B-lymphoblastoid cell lines.

Authors:  M W Taylor; T Long; H Martinez-Valdez; J Downing; G Zeige
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Altered cytokine production in black patients with keloids.

Authors:  R L McCauley; V Chopra; Y Y Li; D N Herndon; M C Robson
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.